Concorde Asset Management, LLC Amgen Inc Transaction History

Concorde Asset Management, LLC

$173 Million
Q3 2024

A detailed history of Concorde Asset Management, LLC transactions in Amgen Inc stock. As of the latest transaction made, Concorde Asset Management, LLC holds 896 shares of AMGN stock, worth $250,888. This represents 0.17% of its overall portfolio holdings.

Number of Shares

896

Previous 888 0.9%

Holding current value

$250,888

Previous $277,000 3.97%

% of portfolio

0.17%

Previous 0.17%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$309.38 - $337.38 $2,475 - $2,699	8 Added 0.9%	896 $288,000
Q2 2024 Aug 12, 2024	BUY	$262.75 - $319.31 $10,772 - $13,091	41 Added 4.84%	888 $277,000
Q1 2024 May 15, 2024	SELL	$268.87 - $324.56 $63,991 - $77,245	-238 Reduced 21.94%	847 $240,000
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $84,125 - $94,903	329 Added 43.52%	1,085 $312,000
Q3 2023 Nov 09, 2023	BUY	$218.65 - $271.46 $165,299 - $205,223	756 New	756 $203,000
Q3 2021 Oct 21, 2021	SELL	$212.27 - $248.7 $181,915 - $213,135	-857 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$233.58 - $259.14 $467 - $518	2 Added 0.23%	857 $209,000
Q1 2021 Apr 27, 2021	SELL	$221.91 - $258.6 $25,519 - $29,739	-115 Reduced 11.86%	855 $212,000
Q4 2020 Jan 29, 2021	BUY	$216.38 - $257.67 $8,222 - $9,791	38 Added 4.08%	970 $224,000
Q3 2020 Oct 23, 2020	BUY	$234.65 - $260.95 $8,682 - $9,655	37 Added 4.13%	932 $238,000
Q2 2020 Jul 20, 2020	BUY	$197.81 - $242.74 $177,039 - $217,252	895 New	895 $210,000
Q1 2020 Apr 22, 2020	SELL	$182.24 - $241.7 $157,819 - $209,312	-866 Closed	0 $0
Q4 2019 Jan 30, 2020	BUY	$189.21 - $243.2 $163,855 - $210,611	866 New	866 $207,000
Q3 2019 Oct 28, 2019	SELL	$174.11 - $208.62 $189,083 - $226,561	-1,086 Closed	0 $0
Q2 2019 Aug 08, 2019	SELL	$166.7 - $195.41 $3,167 - $3,712	-19 Reduced 1.72%	1,086 $201,000
Q1 2019 May 01, 2019	SELL	$180.87 - $203.88 $27,130 - $30,582	-150 Reduced 11.95%	1,105 $212,000
Q4 2018 Jan 25, 2019	SELL	$178.4 - $208.25 $10,882 - $12,703	-61 Reduced 4.64%	1,255 $243,000
Q3 2018 Oct 30, 2018	SELL	$185.29 - $208.89 $9,449 - $10,653	-51 Reduced 3.73%	1,316 $273,000
Q2 2018 Jul 17, 2018	SELL	$166.05 - $186.51 $9,132 - $10,258	-55 Reduced 3.87%	1,367 $252,000
Q1 2018 Apr 24, 2018	BUY	$169.43 - $198.0 $42,357 - $49,500	250 Added 21.33%	1,422 $244,000
Q4 2017 Jan 23, 2018	SELL	$168.79 - $188.59 $18,398 - $20,556	-109 Reduced 8.51%	1,172 $204,000
Q3 2017 Oct 31, 2017	BUY	$167.29 - $191.0 $214,298 - $244,671	1,281	1,281 $237,000

Others Institutions Holding AMGN

# of Institutions

3,123

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concorde Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Concorde Asset Management, LLC with notifications on news.

Account

Concorde Asset Management, LLC Amgen Inc Transaction History